NR4A1 and breast cancer: The NSABP B‐52 trial evaluated pathologic complete response rates in patients with hormone receptor and HER2-positive breast cancer treated with neoadjuvant therapy of docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) with or without concurrent estrogen deprivation therapy.